Hereditary papillary renal cell carcinoma (HPRCC) is a rare type of kidney cancer that is caused by an inherited genetic mutation. It is characterized by the growth of abnormal cells in the lining of the kidney's tubules, which can lead to the formation of tumors. HPRCC is typically diagnosed in adults between the ages of 30 and 50, and is more common in men than women. Treatment typically involves surgery to remove the affected kidney, as well as chemotherapy and/or radiation therapy.

The most common symptom of Hereditary papillary renal cell carcinoma is the presence of a mass or lump in the kidney. Other symptoms may include:

-Pain in the side or lower back

-Blood in the urine

-Fever

-Weight loss

-Fatigue

-Loss of appetite

-Nausea and vomiting

-Swollen lymph nodes

-Abdominal swelling or pain

-High blood pressure

Hereditary papillary renal cell carcinoma (HPRCC) is caused by a mutation in the MET gene. This mutation is inherited in an autosomal dominant pattern, meaning that a person only needs to inherit one copy of the mutated gene from one parent to be at risk for developing HPRCC.

1. Surgery: Surgery is the primary treatment for Hereditary papillary renal cell carcinoma. Depending on the size and location of the tumor, the surgeon may remove the entire kidney (radical nephrectomy) or just the tumor (partial nephrectomy).

2. Targeted Therapy: Targeted therapy is a type of treatment that uses drugs to target specific molecules involved in the growth and spread of cancer cells. Targeted therapies used to treat Hereditary papillary renal cell carcinoma include drugs such as sunitinib, sorafenib, and pazopanib.

3. Immunotherapy: Immunotherapy is a type of treatment that uses the body’s own immune system to fight cancer. Immunotherapy drugs used to treat Hereditary papillary renal cell carcinoma include nivolumab and ipilimum

1. Having a family history of Hereditary papillary renal cell carcinoma
2. Having a mutation in the MET gene
3. Having a mutation in the FH gene
4. Having a mutation in the VHL gene
5. Having a mutation in the SDHB gene
6. Having a mutation in the SDHD gene
7. Having a mutation in the SDHAF2 gene
8. Having a mutation in the MAX gene
9. Having a mutation in the TMEM127 gene
10. Having a mutation in the BAP1 gene
11. Having a mutation in the PBRM1 gene
12. Having a mutation in the SETD2 gene
13. Having a mutation in the KDM5C gene
14. Having a mutation in the KDM6A gene
15. Having a mutation in

Yes, there are treatments available for Hereditary papillary renal cell carcinoma. Treatment options may include surgery, targeted therapy, immunotherapy, and radiation therapy. Medications used to treat Hereditary papillary renal cell carcinoma may include tyrosine kinase inhibitors, mTOR inhibitors, and immunotherapy drugs.